Likewise, total AML cell engraftment was significantly higher in the PB (2.47 ± 1.28% versus 0.60 ± 0.16%, P = 0.0121) (Fig. 3E), BM (11.82 ± 3.70% versus 3.57 ± 0.75%, P = 0.0012) (Fig. 3F), spleen (7.22 ± 1.16% versus 1.88 ± 0.45%, P < 0.0001) (Fig. 3G) and liver (1.73 ± 0.70% versus 0.83 ± 0.26%, P = 0.0265) (Fig. 3H) of the Mettl3-depleted mice than in nondepleted mice after Ara-C treatment. Here, METTL3 is linked to acute myeloid leukemia.